JOP20190143B1 - مثبطات جزيئات صغيرة من عائلة jak لإنزيمات الكيناز - Google Patents

مثبطات جزيئات صغيرة من عائلة jak لإنزيمات الكيناز

Info

Publication number
JOP20190143B1
JOP20190143B1 JOP/2019/0143A JOP20190143A JOP20190143B1 JO P20190143 B1 JOP20190143 B1 JO P20190143B1 JO P20190143 A JOP20190143 A JO P20190143A JO P20190143 B1 JOP20190143 B1 JO P20190143B1
Authority
JO
Jordan
Prior art keywords
kinases
small molecule
molecule inhibitors
jak family
methods
Prior art date
Application number
JOP/2019/0143A
Other languages
English (en)
Inventor
Mark S Tichenor
Michele C Rizzolio
Russell C Smith
Kevin D Kreutter
Tatiana Koudriakova
Kristi Leonard
Aihua Wang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of JOP20190143A1 publication Critical patent/JOP20190143A1/ar
Application granted granted Critical
Publication of JOP20190143B1 publication Critical patent/JOP20190143B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

مركبات 2-((1r,4r)-4-(إيميدازو[4,5-d]بيرولو[2,3-b]بيريدين-1(6H)-يل)سيكلو هكسيل)أسيتونتريل وتركيبات صيدلانية تحتوي عليها وطرق تحضيرها وطرق استخدامها، بما في ذلك طرق علاج حالات مرضية واضطرابات يسببها JAK، مثل داء الأمعاء الالتهابي. الشكل 1
JOP/2019/0143A 2016-12-16 2017-12-15 مثبطات جزيئات صغيرة من عائلة jak لإنزيمات الكيناز JOP20190143B1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662435609P 2016-12-16 2016-12-16
US201762592680P 2017-11-30 2017-11-30
US201762596607P 2017-12-08 2017-12-08
PCT/US2017/066744 WO2018112379A1 (en) 2016-12-16 2017-12-15 Small molecule inhibitors of the jak family of kinases

Publications (2)

Publication Number Publication Date
JOP20190143A1 JOP20190143A1 (ar) 2019-06-13
JOP20190143B1 true JOP20190143B1 (ar) 2023-09-17

Family

ID=61692222

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0143A JOP20190143B1 (ar) 2016-12-16 2017-12-15 مثبطات جزيئات صغيرة من عائلة jak لإنزيمات الكيناز

Country Status (35)

Country Link
US (5) US10294226B2 (ar)
EP (2) EP4086256A1 (ar)
JP (2) JP7291077B2 (ar)
KR (1) KR102352462B1 (ar)
CN (1) CN110088105B (ar)
AU (3) AU2017377069B2 (ar)
CL (1) CL2019001626A1 (ar)
CO (1) CO2019006200A2 (ar)
CR (1) CR20190282A (ar)
CY (1) CY1125460T1 (ar)
DK (1) DK3555097T3 (ar)
EC (1) ECSP19042688A (ar)
ES (1) ES2922379T3 (ar)
HR (1) HRP20220885T1 (ar)
HU (1) HUE059274T2 (ar)
IL (1) IL267275B (ar)
JO (1) JOP20190143B1 (ar)
LT (1) LT3555097T (ar)
MD (1) MD3555097T2 (ar)
MX (2) MX2022004474A (ar)
MY (1) MY196260A (ar)
NI (1) NI201900060A (ar)
NZ (1) NZ795615A (ar)
PE (1) PE20191105A1 (ar)
PH (1) PH12019501254A1 (ar)
PL (1) PL3555097T3 (ar)
PT (1) PT3555097T (ar)
RS (1) RS63500B1 (ar)
SA (1) SA519402216B1 (ar)
SI (1) SI3555097T1 (ar)
SM (1) SMT202200326T1 (ar)
TW (1) TWI777997B (ar)
UA (1) UA125042C2 (ar)
WO (1) WO2018112379A1 (ar)
ZA (1) ZA201904615B (ar)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ751284A (en) 2016-10-03 2022-09-30 Hangzhou Highlightll Pharmaceutical Co Ltd Novel jak1 selective inhibitors and uses thereof
JOP20190090B1 (ar) 2016-10-24 2023-03-28 Astrazeneca Ab مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
EP3689873B1 (en) 2017-01-30 2022-09-14 Astrazeneca AB Estrogen receptor modulators
CN112654610B (zh) 2018-06-15 2024-12-24 里亚塔医药公司 用于抑制IL-17和RORγ的吡唑和咪唑化合物
TW202016110A (zh) * 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
WO2020216936A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor
KR102785014B1 (ko) 2019-06-06 2025-03-20 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태
CN110483514B (zh) 2019-09-16 2022-06-14 启元生物(杭州)有限公司 一种氰基取代的环肼衍生物及其应用
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
AU2021222686B2 (en) * 2020-02-21 2023-06-29 Zhuhai United Laboratories Co., Ltd. Crystalline form of JAK inhibitor and application thereof
MX2022013258A (es) 2020-04-24 2022-11-14 Astrazeneca Ab Formulaciones farmaceuticas.
JP7712955B2 (ja) 2020-04-24 2025-07-24 アストラゼネカ・アクチエボラーグ 癌の治療のための投薬レジメン
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN116925077A (zh) * 2020-09-08 2023-10-24 一又生物(上海)有限公司 吡啶并环类化合物及其制备方法、中间体、组合物和应用
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN113292561A (zh) * 2021-05-22 2021-08-24 中国药科大学 一种二吡咯并吡啶结构的化合物、制备方法和医药用途
CN114432317A (zh) * 2021-05-31 2022-05-06 广州嘉越医药科技有限公司 吡咯并嘧啶类化合物的用途
CN113861194B (zh) * 2021-11-10 2022-07-05 英维沃化工科技(广州)有限公司 一种含吡咯并吡啶双酰胺咪唑类化合物及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
PL351684A1 (en) 1999-04-23 2003-06-02 Smithkline Beecham Plc Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US7192962B2 (en) 2002-05-31 2007-03-20 Schering Corporation Xanthine phosphodiesterase V inhibitor polymorphs
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
WO2007005462A1 (en) 2005-07-01 2007-01-11 Wyeth Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
KR20080026654A (ko) * 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
RU2015105591A (ru) 2008-06-10 2015-08-10 Эббви Инк. Новые трициклические соединения
BR112012004970B1 (pt) 2009-09-03 2020-09-01 Bristol-Myers Squibb Company Inibidores de jak2, seu uso no tratamento de doenças mieloproliferativas e câncer composição farmacêutica que os compreende
JP2011066747A (ja) * 2009-09-18 2011-03-31 Panasonic Corp 弾性波フィルタ
JP5607174B2 (ja) 2009-12-01 2014-10-15 アッヴィ・インコーポレイテッド 新規な三環式化合物
AU2010326030A1 (en) 2009-12-01 2012-06-07 Abbvie Inc. Novel tricyclic compounds
WO2011086053A1 (en) 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
EP2534258B1 (en) 2010-02-10 2017-09-20 Genon Biotechnologies OY Dual activity kinase domains and uses thereof
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
EP2955181B1 (en) 2013-02-08 2019-10-30 Nissan Chemical Corporation Tricyclic pyrrolopyridine compound, and jak inhibitor
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
WO2015174376A1 (ja) 2014-05-14 2015-11-19 日産化学工業株式会社 ３環性化合物及びｊａｋ阻害剤
KR20180011272A (ko) 2015-05-28 2018-01-31 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나제 저해제로서 나프티리딘 화합물
WO2017079639A1 (en) 2015-11-04 2017-05-11 Mayo Foundation For Medical Education And Research Methods and materials for treating autoimmune conditions
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
JOP20190090B1 (ar) 2016-10-24 2023-03-28 Astrazeneca Ab مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
US20200077658A1 (en) 2016-12-16 2020-03-12 Basf Se Pesticidal Compounds
PH12019501328B1 (en) 2016-12-16 2023-05-12 Lilly Co Eli 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors
BR112019010627B1 (pt) 2016-12-16 2023-05-02 Société des Produits Nestlé S.A. Uso de um iso-oligossacarídeo, e método para geração de sabor em um produto alimentício termicamente tratado
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
CN110325530B (zh) 2016-12-16 2022-01-11 辉瑞大药厂 Glp-1受体激动剂及其用途
CA3045567A1 (en) 2017-01-11 2018-07-19 Leo Pharma A/S Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
EP3689873B1 (en) 2017-01-30 2022-09-14 Astrazeneca AB Estrogen receptor modulators
FI3612030T3 (fi) 2017-04-21 2026-03-20 Pahr Therapeutics Inc Ahr:n indoliestäjiä ja niiden käyttötapoja
CN106881892B (zh) 2017-04-27 2020-10-16 双钱集团（江苏）轮胎有限公司 一种轮胎生产用生胎转移系统
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2020216936A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor

Also Published As

Publication number Publication date
MX391936B (es) 2025-03-21
AU2017377069B2 (en) 2020-07-23
MX2022004474A (es) 2023-08-15
US10487083B2 (en) 2019-11-26
KR102352462B1 (ko) 2022-01-17
PE20191105A1 (es) 2019-08-23
EP3555097A1 (en) 2019-10-23
ES2922379T3 (es) 2022-09-14
AU2022204240B2 (en) 2023-10-05
KR20190086779A (ko) 2019-07-23
US20210340143A1 (en) 2021-11-04
RS63500B1 (sr) 2022-09-30
AU2022204240A1 (en) 2022-07-07
CY1125460T1 (el) 2025-05-09
SI3555097T1 (sl) 2022-09-30
ZA201904615B (en) 2021-05-26
PT3555097T (pt) 2022-09-22
EP4086256A1 (en) 2022-11-09
HUE059274T2 (hu) 2022-11-28
US12202831B2 (en) 2025-01-21
CN110088105A (zh) 2019-08-02
BR112019011968A2 (pt) 2019-11-05
NI201900060A (es) 2020-03-16
CR20190282A (es) 2019-08-21
AU2020257068A1 (en) 2020-11-19
IL267275B (en) 2021-07-29
PH12019501254A1 (en) 2020-01-20
CN110088105B (zh) 2022-03-18
MD3555097T2 (ro) 2022-12-31
US20190177321A1 (en) 2019-06-13
MX2019007073A (es) 2019-10-15
JP7291077B2 (ja) 2023-06-14
SA519402216B1 (ar) 2022-10-02
HRP20220885T1 (hr) 2022-12-09
CO2019006200A2 (es) 2019-06-28
CL2019001626A1 (es) 2019-10-04
US11059823B2 (en) 2021-07-13
MY196260A (en) 2023-03-24
NZ755404A (en) 2024-10-25
AU2017377069A1 (en) 2019-06-20
US20180170931A1 (en) 2018-06-21
SMT202200326T1 (it) 2022-09-14
LT3555097T (lt) 2022-08-25
TWI777997B (zh) 2022-09-21
IL267275A (en) 2019-08-29
DK3555097T3 (da) 2022-07-25
NZ795615A (en) 2025-11-28
US10364246B2 (en) 2019-07-30
PL3555097T3 (pl) 2022-10-17
JP2023071709A (ja) 2023-05-23
CA3046965A1 (en) 2018-06-21
US20190177322A1 (en) 2019-06-13
JP2020502113A (ja) 2020-01-23
EP3555097B1 (en) 2022-06-15
UA125042C2 (uk) 2021-12-29
JP7493068B2 (ja) 2024-05-30
US10294226B2 (en) 2019-05-21
ECSP19042688A (es) 2019-06-30
TW201831180A (zh) 2018-09-01
US20190185474A1 (en) 2019-06-20
WO2018112379A1 (en) 2018-06-21
JOP20190143A1 (ar) 2019-06-13

Similar Documents

Publication Publication Date Title
PH12019501355A1 (en) Small molecule inhibitors of the jak family of kinases
JOP20190143A1 (ar) مثبطات جزيئات صغيرة من عائلة jak لإنزيمات الكيناز
EA202090659A1 (ru) СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ
EA201991109A1 (ru) ПРОИЗВОДНЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
EA201891067A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ
DK3489238T3 (da) Farmaceutiske sammensætninger af 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-on- og [1,2,4]triazolo[1,5-c]pteridin-5(6h)-on-derivater som pde1-inhibitorer til behandling af for eksempel neurologiske lidelser
EA201290878A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ, ПСИХИАТРИЧЕСКИХ И МЕТАБОЛИЧЕСКИХ РАССТРОЙСТВ И ЗАБОЛЕВАНИЙ
PH12020551984A1 (en) Small molecule inhibitors of the jak family of kinases
EA201491520A1 (ru) НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ C-met ПРОТЕИНКИНАЗ
EA201991094A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
EA201990973A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
MX2018004517A (es) Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-i l]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak).
EA201890922A1 (ru) Циклические простоэфирные производные пиразоло[1,5-а]пиримидин-3-карбоксамида
EA201991473A1 (ru) Имидазопирролопиридин в качестве ингибиторов киназ семейства jak
TH1901003656A (th) สารยับยั้งที่มีโมเลกุลขนาดเล็กของวงศ์ jak ของไคเนส
EA201991472A1 (ru) Низкомолекулярные ингибиторы киназ семейства jak
EA202190047A1 (ru) Низкомолекулярные ингибиторы киназ семейства jak
AR114969A1 (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak
EA201790795A1 (ru) СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-a]ПИРИМИДИН-4-ОНА
CR20190283A (es) Imidazopyrrolopyridine as inhibitors of the jak family of kinases